Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Pharmaceutical Companies Beefing Up Training for Cancer Specialized MRs
September 11, 2012
- US Pfizer Obtains EU Marketing Authorization for Inlyta
September 11, 2012
- DSP Files Additional Indications for Bipolar I Disorder for Latuda in US
September 11, 2012
- Sanofi Pasteur Says It Cannot Meet MHWL Request to Lower IPV Price
September 11, 2012
- Eisai Receives Australian Approval for Halaven
September 10, 2012
- DSP Revising Midterm Business Plan – Will It Be Able to Hammer Out Effective Measures against Stagnant Domestic Business?
September 10, 2012
- Fuji-Keizai Predicts Antidepressant Market to Exceed 170 Billion Yen in 2020
September 7, 2012
- Kissei Aims for 40% Market Share for Epoetin Alfa at Early Stage
September 7, 2012
- Kyorin to Appoint Yoshida of MSD as Kyorin Pharmaceutical Facilities President
September 7, 2012
- Sunovion Completes Acquisition of Elevation: DSP
September 7, 2012
- Revestive Receives European Market Authorization for Short Bowel Syndrome: Takeda
September 6, 2012
- Nippon Shinyaku Plans Generic Launch to Complement Its New Drug Lineup in Priority Field
September 6, 2012
- AZ Aims to Become Market Leader with Symbicort on Additional Indication for COPD
September 6, 2012
- DSP Submits Imported Drug Registration Application in China for Anticancer Agent Calsed
September 6, 2012
- Meiji Seika Pharma Aims to Bolster Presence with COPD Drug Oxis
September 5, 2012
- Flu Vaccine Deal with BIKEN Hoped to Yield Synergies in Elderly Products: MSD Pres. Alvarez
September 5, 2012
- Anticancer Agent Enzalutamide Approved in the US: Astellas
September 5, 2012
- Halaven Approved in South Korea, To Be Launched in Jan. 2013: Eisai
September 5, 2012
- RaQualia to Focus on Fields Where It Can Exhibit Uniqueness, Compile Biz Strategy in November
September 4, 2012
- “Advancements in Domestic Business is Growth Driver” for Achieving Midterm Business Plan : MTPC President Tsuchiya
September 4, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…